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Abstract. This randomized, double-blind, placebo-controlled study evaluated the efﬁcacy and safety of a new
chewable, rapidly-disintegrating mebendazole (MBZ) 500 mg tablet for Ascaris lumbricoides and Trichuris trichiura
infection treatment. Pediatric patients (1–15 years;N = 295; from Ethiopia and Rwanda) excreting A. lumbricoides and/or
T. trichiura eggswere enrolled. The study had a screening phase (3 days), a double-blind treatment phase (DBP, 19 days),
and an open-label phase (OLP, 7 days). Patients received MBZ or placebo on day 1 of DBP and open-label MBZ on day
19 ± 2 after stool sample collection. Cure rates (primary endpoint), deﬁned as species-speciﬁc egg count of 0 at the end of
DBP, were signiﬁcantly higher in theMBZ group than placebo forA. lumbricoides (83.7% [72/86; 95%CI: 74.2%; 90.8%]
versus 11.1% [9/81; 95%CI: 5.2%; 20.1%],P< 0.001) and for T. trichiura (33.9% [42/124; 95%CI: 25.6%; 42.9%] versus
7.6% [9/119; 95%CI: 3.5%; 13.9%], P < 0.001). Egg reduction rates (secondary endpoint) were signiﬁcantly higher in the
MBZ group than placebo for A. lumbricoides (97.9% [95% CI: 94.4; 99.9] versus 19.2% [95% CI: −5.9; 41.5]; P < 0.001)
and T. trichiura (59.7% [95%CI: 33.9; 78.8] versus 10.5% [95%CI: −16.8; 32.9];P = 0.003). Treatment-emergent adverse
events (TEAEs) in MBZ group occurred in 6.3% (9/144) of patients during DBP and 2.5% (7/278) during OLP. No deaths,
serious TEAEs, or TEAEs leading to discontinuationswere reported. A 500mgchewableMBZ tabletwasmore efﬁcacious
than placebo for the treatment of A. lumbricoides and T. trichiura infections in pediatric patients, and no safety concerns
were identiﬁed.
INTRODUCTION
Soil-transmitted helminth (STH) infections occur in humans
either after inadvertent ingestion of Ascaris lumbricoides
(roundworm) or Trichuris trichiura (whipworm) eggs or Ancy-
lostoma duodenale (hookworm) larvae, or after skin penetra-
tion by infective larvae in the soil of both hookworm species:
A. duodenale andNecator americanus.1 Globally, STHs infect
more than 1.5 billion people, with the highest prevalence in
sub-Saharan Africa, the Americas, China, and East Asia.1,2
A. lumbrocoides infections are responsible for 1 × 106 and
T. trichiura infections for 0.5 × 106 disability adjusted life
years,2 thus accounting for the highest disease burden among
all neglected tropical diseases.3
A vast majority of STH infections are seen in children re-
siding in communities lacking adequate sanitary facilities,
provision of safe potable water, and basic hygiene practices.4
According to theWorldHealthOrganization (WHO) estimate in
2015,more than 270million preschool and 600million school-
aged children are infected or live in areas where there is an
increased risk of STH infections.5,6 STH infections potentially
impact a child’s nutritional status and pose a signiﬁcant threat
to their cognitive and physical development,7,8 consequently,
resulting in poor school performance and absenteeism limit-
ing educational advancement and economic development.7,9
An effective and safe mebendazole (MBZ) 500mg solid oral
tablet formulation is available for the treatment of STH in
children older than one year.10 The WHO recommends that
anthelmintic tablets be crushed andmixed with water for easy
administration in children < 3 years of age. Alternatively, a
chewable tablet may be administered.11 Also, practical limi-
tations, such as bitter taste of crushed medication and risk of
choking, necessitate the availability of age-appropriate for-
mulations for children in the age group of 1–5 years.11
Toaddress these recommendations, achewablestrawberry-
ﬂavored MBZ 500 mg tablet was initially developed as
part of the drug development program for young children.12
Later, a rapidly-disintegrating formulation,whichabsorbswater
in less than a minute to convert to a semi-solid mass was de-
veloped to further improve ease of administration. The primary
objective of this study was to demonstrate the efﬁcacy and
safety of a single dose of this rapidly-disintegrating chew-
able MBZ 500mg tablet formulation compared with placebo in
the treatment of A. lumbricoides and T. trichiura infections in
pediatric patients (1–16 years).
METHODS
The study protocol was approved by the US Food and Drug
Administration, the Ethiopian National Research Ethics Re-
view Committees, the Food, Medicine and Health Adminis-
tration and Control Authority (Ethiopian Regulatory Authority)
as well as the Institutional Review Boards of the University of
Gondar and Jimma University in Ethiopia. The protocol was
also approved by theRwandanNational EthicsCommittee, an
independent committee under the RwandaMinistry of Health,
Kigali, Rwanda. The study was conducted in accordance with
the ethical principles originating in the Declaration of Helsinki,
consistent with the International Council for Harmonization
Good Clinical Practice guidelines, applicable regulatory re-
quirements, and in compliance with the protocol. The parents
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or legally accepted guardians of all children provided an in-
formed consent before participation in the study. In addition,
children ³ 6 years were informed about the study and their
assent was documented.
Study design, randomization, and blinding. This was a
phase 3, randomized, double-blind, placebo-controlled study
conducted at two sites in Ethiopia ( the University of Gondar
and University of Jimma) and one site in Rwanda ( the Rwaza
Health Center, Northern Rwanda) between December 8, 2014
and September 3, 2015. The study consisted of screening
(3 days), a double-blind treatment phase (DBP, 19 ± 2 days)
and follow-up, and an open-label phase (OLP, 7 days) (Figure 1).
Post screening, children with A. lumbricoides and/or
T. trichiura eggs in their stools were randomized (1:1) using
computer-generated random permuted blocks to receive ei-
ther a single 500 mg chewable MBZ tablet or placebo. The
randomization was implemented using an interactive voice
response system. Patients, laboratory personnel, and clini-
cianswere blinded to the randomization. On day 1 of the DBP,
the study staff administered the MBZ or placebo tablet to the
randomized patients. For children 1 year to < 3 years of age,
the tablet was placed in a teaspoon and bottled potable
drinking water was poured into the remaining volume of the
teaspoon (approximately 2–3 mL). The tablet quickly absor-
bed the water, converting into a soft semisolid mass, which
was then easily administered to the patient. Patients older
than 3 years of age chewed the tablet without mixing with
water. On day 19, after providing the follow-up stool samples,
all randomized patients received a MBZ 500 mg chewable
tablet. In the follow-up phase, all patients were evaluated for
safety parameters on day 26.
Study population. Boys and girls (1–16 years of age) living
in high STH-prevalence areas in Ethiopia or Rwanda were
screened for STHeggs in stools.ChildrenwithA. lumbricoides
and/or T. trichiura eggs in their stools were eligible for ran-
domization. Children positive for hookworm along with one or
both of the previously mentioned STH species were also eli-
gible. Children had to be otherwise healthy based on medical
history, physical examination, vital signs, hemoglobin, and
concomitantmedications for inclusion. Exclusion criteriawere
as follows: children with a history or a medical disorder
causing difﬁculty in chewing or swallowing, signiﬁcant anemia
(< 8 g/dL), active diarrhea (passage of ³ 3 loose or liquid stools
per day), signiﬁcant wasting (moderate and severe-below
minus two standard deviations frommedian weight for height
of reference population), or hypersensitivity to MBZ or any
inert ingredients in the chewable formulation or other medi-
cations in the benzimidazole class, and girls ³ 9 years of age
having a positive urine pregnancy test at screening or ran-
domization. In addition, children who had taken MBZ or any
other treatment of STH infection, who had received an
investigational drug (including vaccines) or used an in-
vestigational medical device, or who had any preplanned
surgery procedures within 30 days before entering into the
study were also excluded.
Efﬁcacy assessments.A total of two stool samples (days 1
and 19 [±2]) were obtained from each patient. Two Kato-Katz
smears were prepared from each of the stool samples to re-
duce the number of false negative test results, and hence
enhance the accuracy of the efﬁcacy estimates.13,14 The av-
erage egg counts for A. lumbricoides or T. trichiura from the
stool sample collected in pretreatment (day 1) were used as
FIGURE 1. Study design and patient disposition.
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the baseline values, and the average egg counts from the
posttreatment (day 19) stool sample were used as the end-
point values for the statistical analysis.
Primary endpoint. The primary efﬁcacy endpoint was the
cure rate for A. lumbricoides and T. trichiura at the end of the
double-blind (DB) treatment period (day 19). The cure rate was
calculated as the percentage of randomized patients with
a zero egg count for A. lumbricoides or T. trichiura (no eggs
present in either smear) posttreatment.
Secondary endpoint. The secondary efﬁcacy endpoint was
the egg count reduction rate (ERR) for A. lumbricoides and
T. trichiura at the end of theDB treatment period. TheERRwas
calculated by evaluating the percentage change in the group
arithmetic mean egg count posttreatment compared with
baseline for each group.15,16
Exploratory endpoints. Exploratory efﬁcacy endpoints in-
cluded the cure rate and ERR at the end of the DB treatment
period for hookworm.
Safety and tolerability assessments.Safety assessments
included evaluation of vital signs, physical examinations,
treatment-emergent adverse events (TEAEs), and serious
AEs. The TEAEs were assessed based on the direct obser-
vations of the investigator, the patient, or as reported by the
patient, parent, or guardian. The TEAEs were assessed sep-
arately for the DBP and the OLP. Ease of administration of
drug and tolerability were also reported.
Statistical analysis. Sample size.A total of 50 patients with
A. lumbricoides and 200 with T. trichiura were targeted to be
enrolled in the study. This was required to detect a differ-
ence in cure rate between MBZ and placebo of 60% for
A. lumbricoides and 20% for T. trichiura with a power of 90%
at the overall two-sided type I error rate of 0.05 based on
Fisher’s exact test. This calculation was based on the ranges
for cure-rates reported in previous studies.17
Null hypotheses. Two null hypotheses were tested se-
quentially. The ﬁrst null hypothesis was that the cure rate of
A. lumbricoides after treatment with a single dose of a 500mg
chewable tablet of MBZ or placebo was not different. The
second null hypothesis was that the cure rate of T. trichiura
after treatment with a single dose of a 500mg chewable tablet
of MBZ or placebo was not different. The second hypothesis
was to be evaluated only if the ﬁrst null hypothesis was
rejected at the P = 0.05 level.
Efﬁcacy and safety analysis. The primary efﬁcacy analysis
was based on the intent-to-treat (ITT) population deﬁned as all
randomized patients with a positive pretreatment stool sam-
ple. Efﬁcacy for the two infections was calculated separately,
and patients with both infections were included in the analysis
of both. For the primary efﬁcacy endpoints, the Cochran–
Mantel–Haenszel test controlling the effect of site was used to
compare the cure rates between the two treatment groups.
Patients missing the posttreatment stool sample were con-
sidered not cured.
For the secondary efﬁcacy endpoints, the 95% conﬁdence
intervals for theERRweredeterminedbybootstrap analysis. A
permutation test was performed to assess differences in the
ERR between MBZ (500 mg) and the placebo arm.
TheDBPsafety analysis population includedall randomized
patients who received one dose of study drug at baseline. The
OLP safety analysis population included all patients who re-
ceived the 500 mg MBZ on day 19. Exploratory and safety
analyses were summarized descriptively.
RESULTS
Patient disposition and characteristics. Of 792 children
screened, 295 were enrolled and randomized of which 278
(94.2%) patients completed the study (MBZ: n = 141, placebo:
n = 137). The most common reason for discontinuation was
withdrawal of consent (MBZ: 7 [4.7%], placebo: 5 [3.4%]).
None of the patients discontinued the study because of non-
compliance or TEAEs (Figure 1). Patients enrolled were up to
15 years of age and the mean (SD) age of the patients was 7.8
(3.18) years (Table 1). There were similar proportions of
boys and girls in both treatment groups, as well as within
each group. At baseline, 167 patients were infected with
A. lumbricoides (MBZ: N = 86, placebo: N = 81) and 243 with
T. trichiura (MBZ: n = 124, placebo: n = 119); 115 were coin-
fectedwithboth, and13were infectedwith hookwormspecies
in addition to A. lumbricoides and T. trichiura.
Efﬁcacy. Primary endpoint. Cure rates were signiﬁ-
cantly higher in patients receiving MBZ versus placebo
for A. lumbricoides (MBZ: 83.7% [95% CI: 74.2%; 90.8%],
placebo: 11.1% [95% CI: 5.2%; 20.1%]; P < 0.001) and
T. trichiura (MBZ: 33.9% [95% CI: 25.6%; 42.9%], placebo:
7.6% [95% CI: 3.5%; 13.9%)]; P < 0.001) (Table 2). The cure
rate ofA. lumbricoides for patients in all age groups (> 3 years,
3–6 years and 7–15 years) was ³ 80% for the MBZ group. The
cure rate ofT. trichiura for patients in all agegroupswas>20%
for the MBZ group with the 7–15 years group exhibiting
the highest cure rate (37.1%) among all the age groups
(Supplemental Table 1). Both null hypotheses that the MBZ
and placebo group demonstrated similar efﬁcacy were,
therefore, rejected.
Secondary endpoint. The ERRs as measured by group ar-
ithmetic mean were also signiﬁcantly different between MBZ
and placebo in patients infected with A. lumbricoides (MBZ:
TABLE 1
Patient demographics and baseline characteristics (ITT population)
Mebendazole






Boys 71 (47.7) 72 (49.3) 143 (48.5)
Girls 78 (52.3) 74 (50.7) 152 (51.5)
Age (years)
Mean (SD) 7.9 (3.27) 7.7 (3.09) 7.8 (3.18)
Baseline BMI (kg/m2)
Mean (SD) 15.7 (1.7) 15.7 (1.9) 15.7 (1.8)
A. lumbricoides egg
count, n (%)
No infection 63 (42.3) 65 (44.5) 128 (43.4)
Light (1–4,999 eggs/gm) 34 (22.8) 31 (21.2) 65 (22.0)
Moderate (5,000–49,999
eggs/gm)
45 (30.2) 44 (30.1) 89 (30.2)
Heavy (³ 50,000 eggs/gm) 7 (4.7) 6 (4.1) 13 (4.4)
T. trichiura egg count, n (%)
No Infection 25 (16.8) 27 (18.5) 52 (17.6)
Light (1–999 eggs/gm) 100 (67.1) 102 (69.9) 202 (68.5)
Moderate (1,000–9,999
eggs/gm)
24 (16.1) 17 (11.6) 41 (13.9)
Heavy (³ 10,000 eggs/gm) 0 0 0
Hook worm egg count, n (%)
No infection 145 (97.3) 137 (93.8) 282 (95.6)
Light (1–1,999 eggs/gm) 4 (2.7) 8 (5.5) 12 (4.1)
Moderate (2,000–3,999
eggs/gm)
0 (0) 1 (0.7) 1 (0.3)
Heavy (³ 4,000 eggs/gm) 0 0 0
BMI = body mass index; ITT = intent-to-treat.
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97.9%, [95% CI: 94.4; 99.9]; placebo: 19.2%, [95% CI: −5.9;
41.5]; P < 0.001) and T. trichiura (MBZ: 59.7% [95% CI: 33.9;
78.8]; placebo: 10.5%[95%CI:−16.8; 32.9],P=0.003) (Table 2).
Exploratory endpoint.At baseline, 13 patients were infected
with hookworm species (MBZ: n = 4, placebo: n = 9). The cure
rate and ERR for the MBZ group was 100%. For the placebo
group, the cure rate was 22.2% and the ERR was 17.5%.
Safety. There were no deaths, serious AEs, or TEAEs
leading to discontinuation in this study. Overall, the incidence
of TEAEs was generally comparable between the groups over
the DBP, with similar rates of TEAEs for MBZ (9/144 [6.3%])
and placebo (8/140 [5.7%]); TEAEs were mild or moderate in
intensity. The most common TEAEs in both groups included
gastrointestinal disorders (MBZ: 3/144 [2.1%], placebo: 2/140
[1.4%]) and infections (MBZ: 3/144 [2.1%], placebo: 4/140
[2.9%]) (Table 3). Abdominal pain (n=1), abdominal distension
(n = 2), and rash (n = 1) were the only TEAEs considered
possibly related to MBZ treatment.
The overall incidence of TEAEs in the OLP (day 19–day 26)
was 2.5% (7/278 patients), with diarrhea being the most
common (2/278; 0.7%). Diarrhea (n = 2), abdominal pain (n = 1),
and vomiting (n = 1) were considered possibly related to
MBZ. No clinically signiﬁcant changes were observed in vital
signs or physical examination.
Tolerability.Of the 284 patients receiving the study drug or
placebo in the DBP of the study, 259 (91.2%) chewed the
tablets, and 25 (8.8%) patients received the study drug mixed
with water in a spoon. There were no instances of choking or
vomiting in either treatment group. Therewere three instances
of gagging (MBZ: n = 2, placebo: n = 1) and two instances of
difﬁculty in swallowing in theplacebogroup; all instanceswere
in patientswhowere<3 years old (Table 4). In theOLP, among
the 278patients, 24 (8.6%) received the study drugmixedwith
water in a spoon, and the remaining 254 (91.4%) patients
chewed the tablets. There were no instances of choking,
vomiting, or gagging. In patients < 3 years old, there was one
instance of difﬁculty in swallowing medicine and two in-
stances of consuming more than half the medication and
spitting it out.
DISCUSSION
The present phase 3, randomized, placebo-controlled,
double-blind study demonstrated that a single 500 mg
chewable, rapidly-disintegrating tablet of MBZ is effective for
the treatment of A. lumbricoides and T. trichiura infections in
pediatric patients as indicated by signiﬁcantly higher cure
rates and ERRs comparedwith placebo for both STH species.
The MBZ treatment demonstrated a consistent safety and
tolerability proﬁle to that of earlier studies, with no safety
concerns identiﬁed.
In 2001, the World Health Assembly resolved to eliminate
STH as a childhood health-problem. One of the targets was to
regularly administer preventive therapy to at least 75% of
school-aged children at high risk of STH infection associated
morbidity by 2010. However, this was achieved in only about
one-third of the previously mentioned population. In 2011, the
WHO revised its strategic plan to eliminate morbidity caused
by STH (deﬁned as a prevalence of < 1% moderate to heavy
infections) as a health issue in children by 2020. This includes
guidance to STH-endemic region governments, partners, and
donors with therapy requirements to achieve the goal.18
TABLE 2
The cure rate and egg reduction rate in pediatric patients infected with A. lumbricoides and T. trichiura (ITT population)
A. lumbricoides T. trichiura
Mebendazole 500 mg (n = 86) Placebo (n = 81) Mebendazole 500 mg (n = 124) Placebo (n = 119)
Baseline (eggs/gm)
n 86 81 124 119
Mean (SD) 17,610.1 (23,476.8) 16,959.6 (20,684.0) 647.8 (1,256.2) 584.5 (930.1)
Cure at day 19
n (%) 72 (83.7) 9 (11.1) 42 (33.9) 9 (7.6)
95% CI (74.2; 90.8) (5.2; 20.1) (25.6; 42.9) (3.5; 13.9)
P value < 0.001 < 0.001
Egg count at day 19 (eggs/gm)
n 81 76 118 112
Mean (SD) 366.7 (2,325.3) 13,706.7 (23,168.3) 260.7 (1,042.9) 523.0 (1,020.9)
Egg count reduction rate (%) 97.9 19.2 59.7 10.5
P value < 0.001 0.003
95% CI (94.4; 99.9) (−5.9; 41.5) (33.9; 78.8) (−16.8; 32.9)
CI = conﬁdence interval; gm = gram; ITT = intent-to-treat; SD = standard deviation.
TABLE 3
Treatment-emergent adverse events in the double-blind phase (safety
analysis set)
Mebendazole 500 mg
(n = 144) n (%)
Placebo
(n = 140) n (%)
Total no. children with any TEAE 9 (6.3) 8 (5.7)
Gastrointestinal disorders 3 (2.1) 2 (1.4)
Abdominal distension 2 (1.4) 1 (0.7)
Abdominal pain 1 (0.7) 1 (0.7)
Infections and infestations 3 (2.1) 4 (2.9)
Gastroenteritis 1 (0.7) 0
Nasopharyngitis 1 (0.7) 2 (1.4)
Tinea infestation 1 (0.7) 0
Conjunctivitis 0 1 (0.7)
Conjunctivitis bacterial 0 1 (0.7)
Tonsillitis 0 1 (0.7)
Metabolism and nutrition disorders 1 (0.7) 0
Vitamin A deﬁciency 1 (0.7) 0
Respiratory, thoracic, and
mediastinal disorders
1 (0.7) 2 (1.4)
Cough 1 (0.7) 2 (1.4)
Skin and subcutaneous tissue
disorders
1 (0.7) 0
Rash pruritic 1 (0.7) 0
Eye disorders 0 1 (0.7)
Night blindness 0 1 (0.7)
TEAE = treatment-emergent adverse event.
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Oneof themajor challenges in achieving this goal is thepoor
adherence of children to antihelminthics due to tolerability
issues and difﬁculty in administration. To overcome this
challenge, the WHO recommends that for children 1 to < 3
years of age, chewable tablets should be crushed and
given with a small quantity of water.11 Consistent with the
WHO recommendations, a rapidly-disintegrating chewable
strawberry-ﬂavored 500 mg MBZ tablet was developed. The
tablet does not require crushing and converts into a semisolid
mass when a small amount of water is added, thereby im-
proving palatability and ease of administration of MBZ in
preschool and school-aged children.
The two countries chosen to conduct this study, Ethiopia
and Rwanda, have been shown to have a high prevalence of
STH infections both among preschool-aged19 and school-
aged children.20,21 The efﬁcacy results of this study are similar
to those reported previously in literature.(16,22–24) The cure rate
for A. lumbricoides (83.7%) and T. trichiura (33.9%) was in the
range of other studies using 500 mg single-dose MBZ
(72.5–100.0% and 8.4–100.0% respectively).16,24 In our study,
analysis by age group for each helminth species demon-
strated similar cure rates across all three age groups. These
results were based on a small sample size in younger age
subgroups (< 3 and 3–6 years).
Data from previous studies with MBZ 500 mg solid oral
tablet dosed once daily for A. lumbricoides demonstrated
ERRs ranging from 89.8% to 100.0% and 31.6% to 93.0% for
T. trichiura.17,25 The ERR of A. lumbricoides (97.9%) and
T. trichiura (57.9%) reported in the current study fall within the
reported range. The cure rates and ERR rates reported with the
chewable rapidly-disintegrating formulationarecomparablewith
those observed with the solid oral tablet. This is an important
ﬁnding given theWHO estimates that approximately 250 million
infected or at-risk children are < 5 years of age. Only a small
number of patients had heavy A. lumbricoides infestation (i.e.,
³ 50,000 eggs/gm of feces; n = 13), and no patients had heavy
T. trichiura infestation (³ 10,000 eggs/gm). Hence, no conclu-
sions can be drawn on the efﬁcacy and safety of the chewable
MBZ tablet in patients with infestations of heavy intensity.
No deaths or serious AEs were observed. The incidence of
TEAEs in thepresent study (6.3%)was lower than in aprevious
safety study (11%) with an earlier version of MBZ chewable
tablet.13,26 All TEAEs were considered mild or moderate and
most were not considered related to MBZ administration. The
present study also demonstrated thatMBZ can be used safely
in children aged 12–36 months. In this study, the tablet was
successfully chewedby all patientswhowere ³ 3 years of age.
For patients < 3 years of age, mixing with water (without
crushing) allowed for easy administration as a semisolid mass
to 25 patients. Two patients in the MBZ group reported gag-
ging in DBP and one instance of difﬁculty in swallowing and
two instances of spitting out medication after swallowing in
OLP, but there were no instances of choking.
CONCLUSIONS
The present study demonstrates that a single-dose, chew-
able MBZ 500 mg tablet is efﬁcacious in the treatment
of A. lumbricoides and T. trichiura infections in pediatric pa-
tients between 1 and 15 years of age. This chewable, rapidly-
disintegrating formulation has a safety and tolerability proﬁle
consistent with previous formulations and could facilitate the
treatment of young children who have difﬁculty swallowing
a tablet, thus potentially expanding the population of at-risk
children that can be effectively treated in mass drug adminis-
tration programs for STH infections.
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TABLE 4
Drug administration tolerability proﬁle in the double-blind phase
(safety analysis set)
Mebendazole







Chewed 131 (91.0) 128 (91.4) 259 (91.2)
Swallowed 0 0 0
Mixed with water and
given with spoon
13 (9.0) 12 (8.6) 25 (8.8)
Tolerability, n (%)
Choking 0 0 0
Gagging 2 (1.4) 1 (0.7) 3 (1.1)
Vomiting 0 0 0
Difﬁculty swallowing 0 2 (1.4)* 2 (0.7)
Spitting out of
medication
0 2 (1.4)* 2 (0.7)
Refusal to take the
medication
0 2 (1.4)* 2 (0.7)
* The same two patients in the placebo group reported difﬁculty swallowing, spit out, and
refused medication.
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